Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Global tuberculosis prevention: should we start from the beginning?

Sotgiu G, Goletti D, Matteelli A.

Eur Respir J. 2019 Sep 12;54(3). pii: 1901394. doi: 10.1183/13993003.01394-2019. Print 2019 Sep. No abstract available.

PMID:
31515266
2.

QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis.

Sotgiu G, Saderi L, Petruccioli E, Aliberti S, Piana A, Petrone L, Goletti D.

J Infect. 2019 Aug 29. pii: S0163-4453(19)30258-0. doi: 10.1016/j.jinf.2019.08.018. [Epub ahead of print]

PMID:
31473271
3.

Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometry.

Alonzi T, Petruccioli E, Vanini V, Fimia GM, Goletti D.

Eur J Histochem. 2019 Jun 26;63(2). doi: 10.4081/ejh.2019.3044.

4.

IP-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay.

Palucci I, Battah B, Salustri A, De Maio F, Petrone L, Ciccosanti F, Sali M, Bondet V, Duffy D, Fimia GM, Goletti D, Delogu G.

Int J Med Microbiol. 2019 Jul;309(5):299-306. doi: 10.1016/j.ijmm.2019.05.005. Epub 2019 May 22.

PMID:
31147175
5.

Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.

Cantini F, Niccoli L, Capone A, Petrone L, Goletti D.

Expert Opin Drug Saf. 2019 May;18(5):415-425. doi: 10.1080/14740338.2019.1612872. Epub 2019 May 8. Review.

PMID:
31066297
6.

Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases.

Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Massafra U, Baldi G, Navarra A, Scrivo R, Mastroianni C, Sauzullo I, Esposito C, Palmieri F, Cantini F, Goletti D.

J Infect. 2019 Jul;79(1):15-23. doi: 10.1016/j.jinf.2019.04.010. Epub 2019 Apr 11.

PMID:
30981891
7.

Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.

Gualano G, Mencarini P, Musso M, Mosti S, Santangelo L, Murachelli S, Cannas A, Di Caro A, Navarra A, Goletti D, Girardi E, Palmieri F.

PLoS One. 2019 Feb 28;14(2):e0212948. doi: 10.1371/journal.pone.0212948. eCollection 2019.

8.

Severe chest allodynia as an unusual first presentation of hydatid disease: a case report.

Coluzzi F, Meniconi RL, Caruso D, Rivosecchi F, Petrone L, Goletti D, Ettorre GM.

BMC Infect Dis. 2019 Jan 9;19(1):37. doi: 10.1186/s12879-019-3670-7.

9.

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables.

Niccoli L, Nannini C, Blandizzi C, Mantarro S, Mosca M, Di Munno O, Goletti D, Benucci M, Gobbi FL, Cassarà E, Kaloudi O, Cantini F.

Ther Clin Risk Manag. 2018 Oct 24;14:2097-2111. doi: 10.2147/TCRM.S175772. eCollection 2018.

10.

Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis.

Lubbers R, Sutherland JS, Goletti D, de Paus RA, van Moorsel CHM, Veltkamp M, Vestjens SMT, Bos WJW, Petrone L, Del Nonno F, Bajema IM, Dijkman K, Verreck FAW, Walzl G, Gelderman KA, Groeneveld GH, Geluk A, Ottenhoff THM, Joosten SA, Trouw LA.

Front Immunol. 2018 Oct 23;9:2427. doi: 10.3389/fimmu.2018.02427. eCollection 2018.

11.

The Mycobacterial HBHA Protein: A Promising Biomarker for Tuberculosis.

De Maio F, Squeglia F, Goletti D, Delogu G.

Curr Med Chem. 2019;26(11):2051-2060. doi: 10.2174/0929867325666181029165805. Review.

PMID:
30378481
12.

Can we predict tuberculosis cure? What tools are available?

Goletti D, Lindestam Arlehamn CS, Scriba TJ, Anthony R, Cirillo DM, Alonzi T, Denkinger CM, Cobelens F.

Eur Respir J. 2018 Nov 8;52(5). pii: 1801089. doi: 10.1183/13993003.01089-2018. Print 2018 Nov. Review.

13.

Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection.

Petruccioli E, Chiacchio T, Vanini V, Cuzzi G, Codecasa LR, Ferrarese M, Schininà V, Palmieri F, Ippolito G, Goletti D.

Sci Rep. 2018 Oct 23;8(1):15626. doi: 10.1038/s41598-018-33825-w.

14.

Combined use of Quantiferon and HBHA-based IGRA supports tuberculosis diagnosis and therapy management in children.

Sali M, Buonsenso D, D'Alfonso P, De Maio F, Ceccarelli M, Battah B, Palucci I, Chiacchio T, Goletti D, Sanguinetti M, Valentini P, Delogu G.

J Infect. 2018 Dec;77(6):526-533. doi: 10.1016/j.jinf.2018.09.011. Epub 2018 Sep 26.

PMID:
30267797
15.

First description of agonist and antagonist IP-10 in urine of patients with active TB.

Petrone L, Bondet V, Vanini V, Cuzzi G, Palmieri F, Palucci I, Delogu G, Ciccosanti F, Fimia GM, Blauenfeldt T, Ruhwald M, Duffy D, Goletti D.

Int J Infect Dis. 2019 Jan;78:15-21. doi: 10.1016/j.ijid.2018.09.001. Epub 2018 Sep 7.

16.

PE_PGRS3 of Mycobacterium tuberculosis is specifically expressed at low phosphate concentration, and its arginine-rich C-terminal domain mediates adhesion and persistence in host tissues when expressed in Mycobacterium smegmatis.

De Maio F, Battah B, Palmieri V, Petrone L, Corrente F, Salustri A, Palucci I, Bellesi S, Papi M, Rubino S, Sali M, Goletti D, Sanguinetti M, Manganelli R, De Spirito M, Delogu G.

Cell Microbiol. 2018 Dec;20(12):e12952. doi: 10.1111/cmi.12952. Epub 2018 Sep 26.

PMID:
30192424
17.

An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease.

Kik SV, Schumacher S, Cirillo DM, Churchyard G, Boehme C, Goletti D, Rangaka MX, Denkinger CM, Lienhardt C, Gilpin C, Matteelli A, Cobelens F.

Eur Respir J. 2018 Oct 25;52(4). pii: 1800946. doi: 10.1183/13993003.00946-2018. Print 2018 Oct.

PMID:
30139776
18.

Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis.

Santos VS, Goletti D, Kontogianni K, Adams ER, Molina-Moya B, Dominguez J, Crudu V, Martins-Filho PRS, Ruhwald M, Lawson L, Bimba JS, Garcia-Basteiro AL, Petrone L, Kabeer BS, Reither K, Cuevas LE.

Clin Microbiol Infect. 2019 Feb;25(2):169-177. doi: 10.1016/j.cmi.2018.07.017. Epub 2018 Aug 2.

19.

Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection.

Petrone L, Vanini V, Chiacchio T, Petruccioli E, Cuzzi G, Schininà V, Palmieri F, Ippolito G, Goletti D.

Tuberculosis (Edinb). 2018 Jul;111:147-153. doi: 10.1016/j.tube.2018.06.005. Epub 2018 Jun 12.

20.

Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions.

Blauenfeldt T, Petrone L, Del Nonno F, Baiocchini A, Falasca L, Chiacchio T, Bondet V, Vanini V, Palmieri F, Galluccio G, Casrouge A, Eugen-Olsen J, Albert ML, Goletti D, Duffy D, Ruhwald M.

Front Immunol. 2018 Jul 5;9:1456. doi: 10.3389/fimmu.2018.01456. eCollection 2018.

21.

Antitubercular and anti-inflammatory properties screening of natural products from Plectranthus species.

Andrade JM, Custódio L, Romagnoli A, Reis CP, Rodrigues MJ, Garcia C, Petruccioli E, Goletti D, Faustino C, Fimia GM, Rijo P.

Future Med Chem. 2018 Jul 1;10(14):1677-1691. doi: 10.4155/fmc-2018-0043. Epub 2018 Jun 29.

PMID:
29957070
22.

Diagnostic imaging of hepatic tuberculosis: case series.

Schininà V, Albarello F, Cristofaro M, Di Stefano F, Fusco N, Cuzzi G, Arend SM, Goletti D, Busi Rizzi E.

Int J Tuberc Lung Dis. 2018 Jul 1;22(7):779-787. doi: 10.5588/ijtld.17.0710.

PMID:
29914604
23.

Human CD4 T-Cells With a Naive Phenotype Produce Multiple Cytokines During Mycobacterium Tuberculosis Infection and Correlate With Active Disease.

Orlando V, La Manna MP, Goletti D, Palmieri F, Lo Presti E, Joosten SA, La Mendola C, Buccheri S, Ottenhoff THM, Dieli F, Caccamo N.

Front Immunol. 2018 May 23;9:1119. doi: 10.3389/fimmu.2018.01119. eCollection 2018.

24.

Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs.

Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F.

Expert Rev Anti Infect Ther. 2018 Jun;16(6):501-512. doi: 10.1080/14787210.2018.1483238. Epub 2018 Jun 12. Review.

PMID:
29848120
25.

Clinical isolates of the modern Mycobacterium tuberculosis lineage 4 evade host defense in human macrophages through eluding IL-1β-induced autophagy.

Romagnoli A, Petruccioli E, Palucci I, Camassa S, Carata E, Petrone L, Mariano S, Sali M, Dini L, Girardi E, Delogu G, Goletti D, Fimia GM.

Cell Death Dis. 2018 May 24;9(6):624. doi: 10.1038/s41419-018-0640-8.

26.

Impact of antiretroviral and tuberculosis therapies on CD4+ and CD8+ HIV/M. tuberculosis-specific T-cell in co-infected subjects.

Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, La Manna MP, Orlando V, Pinnetti C, Sampaolesi A, Antinori A, Caccamo N, Goletti D.

Immunol Lett. 2018 Jun;198:33-43. doi: 10.1016/j.imlet.2018.04.001. Epub 2018 Apr 7.

27.

Managing latent tuberculosis infection and tuberculosis in children.

Carvalho I, Goletti D, Manga S, Silva DR, Manissero D, Migliori G.

Pulmonology. 2018 Mar - Apr;24(2):106-114. doi: 10.1016/j.rppnen.2017.10.007. Epub 2018 Mar 2. Review.

28.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).

Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J.

Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S10-S20. doi: 10.1016/j.cmi.2017.12.025. Epub 2018 Feb 6. Review.

29.

Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease.

Goletti D, Lee MR, Wang JY, Walter N, Ottenhoff THM.

Respirology. 2018 May;23(5):455-466. doi: 10.1111/resp.13272. Epub 2018 Feb 18. Review.

30.

Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages.

Paolino M, Brindisi M, Vallone A, Butini S, Campiani G, Nannicini C, Giuliani G, Anzini M, Lamponi S, Giorgi G, Sbardella D, Ferraris DM, Marini S, Coletta M, Palucci I, Minerva M, Delogu G, Pepponi I, Goletti D, Cappelli A, Gemma S, Brogi S.

ChemMedChem. 2018 Mar 6;13(5):422-430. doi: 10.1002/cmdc.201700759. Epub 2018 Feb 14.

PMID:
29334428
31.

Impaired IFN-α-mediated signal in dendritic cells differentiates active from latent tuberculosis.

Parlato S, Chiacchio T, Salerno D, Petrone L, Castiello L, Romagnoli G, Canini I, Goletti D, Gabriele L.

PLoS One. 2018 Jan 10;13(1):e0189477. doi: 10.1371/journal.pone.0189477. eCollection 2018.

32.

Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection.

Palucci I, Matic I, Falasca L, Minerva M, Maulucci G, De Spirito M, Petruccioli E, Goletti D, Rossin F, Piacentini M, Delogu G.

J Intern Med. 2018 Mar;283(3):303-313. doi: 10.1111/joim.12714. Epub 2017 Dec 4.

PMID:
29205566
33.

A T-cell diagnostic test for cystic echinococcosis based on Antigen B peptides.

Petrone L, Vanini V, Amicosante M, Corpolongo A, Gomez Morales MA, Ludovisi A, Ippolito G, Pozio E, Teggi A, Goletti D.

Parasite Immunol. 2017 Dec;39(12). doi: 10.1111/pim.12499.

34.

Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey.

Amicosante M, D'Ambrosio L, Munoz M, Mello FCQ, Tebruegge M, Chegou NN, Seghrouchni F, Centis R, Goletti D, Bothamley G, Migliori GB; TB Diagnostic Survey Working Group.

J Bras Pneumol. 2017 Sep-Oct;43(5):380-392. doi: 10.1590/S1806-37562017000000219. English, Portuguese.

35.

Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection.

Chiacchio T, Delogu G, Vanini V, Cuzzi G, De Maio F, Pinnetti C, Sampaolesi A, Antinori A, Goletti D.

PLoS One. 2017 Aug 24;12(8):e0183846. doi: 10.1371/journal.pone.0183846. eCollection 2017.

36.

New synthetic lipid antigens for rapid serological diagnosis of tuberculosis.

Jones A, Pitts M, Al Dulayymi JR, Gibbons J, Ramsay A, Goletti D, Gwenin CD, Baird MS.

PLoS One. 2017 Aug 14;12(8):e0181414. doi: 10.1371/journal.pone.0181414. eCollection 2017.

37.

Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis.

Petruccioli E, Vanini V, Chiacchio T, Cuzzi G, Cirillo DM, Palmieri F, Ippolito G, Goletti D.

Tuberculosis (Edinb). 2017 Sep;106:38-43. doi: 10.1016/j.tube.2017.06.002. Epub 2017 Jun 27.

38.

Differential Recognition of Mycobacterium tuberculosis-Specific Epitopes as a Function of Tuberculosis Disease History.

Scriba TJ, Carpenter C, Pro SC, Sidney J, Musvosvi M, Rozot V, Seumois G, Rosales SL, Vijayanand P, Goletti D, Makgotlho E, Hanekom W, Hatherill M, Peters B, Sette A, Arlehamn CSL.

Am J Respir Crit Care Med. 2017 Sep 15;196(6):772-781. doi: 10.1164/rccm.201706-1208OC.

39.

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics.

Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D.

Mediators Inflamm. 2017;2017:8909834. doi: 10.1155/2017/8909834. Epub 2017 Jun 1. Review.

40.

Standard operating procedures for tuberculosis care.

Solovic I, Abubakar I, Sotgiu G, Dara M, Goletti D, Duarte R, Aliberti S, de Benedictis FM, Ward B, Teixeira V, Gratziou C, Migliori GB.

Eur Respir J. 2017 Jun 1;49(6). pii: 1700515. doi: 10.1183/13993003.00515-2017. Print 2017 Jun. No abstract available.

41.

Long-lasting tuberculous pleurisy.

Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, Codecasa LR, Ottenhoff TH, Denkinger CM, Goletti D.

Eur Respir J. 2017 May 25;49(5). pii: 1700356. doi: 10.1183/13993003.00356-2017. Print 2017 May. No abstract available.

42.

Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis.

Camassa S, Palucci I, Iantomasi R, Cubeddu T, Minerva M, De Maio F, Jouny S, Petruccioli E, Goletti D, Ria F, Sali M, Sanguinetti M, Manganelli R, Rocca S, Brodin P, Delogu G.

Front Cell Infect Microbiol. 2017 Apr 21;7:137. doi: 10.3389/fcimb.2017.00137. eCollection 2017.

43.

Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, Goletti D.

Semin Arthritis Rheum. 2017 Oct;47(2):183-192. doi: 10.1016/j.semarthrit.2017.03.008. Epub 2017 Mar 22. Review.

PMID:
28413099
44.

Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages.

La Manna MP, Orlando V, Dieli F, Di Carlo P, Cascio A, Cuzzi G, Palmieri F, Goletti D, Caccamo N.

PLoS One. 2017 Feb 16;12(2):e0171358. doi: 10.1371/journal.pone.0171358. eCollection 2017.

45.

The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications.

Girardi E, Sañé Schepisi M, Goletti D, Bates M, Mwaba P, Yeboah-Manu D, Ntoumi F, Palmieri F, Maeurer M, Zumla A, Ippolito G.

Int J Infect Dis. 2017 Mar;56:45-53. doi: 10.1016/j.ijid.2017.01.018. Epub 2017 Jan 30. Review.

46.

Characterization of the CD4 and CD8 T-cell response in the QuantiFERON-TB Gold Plus kit.

Petruccioli E, Chiacchio T, Pepponi I, Vanini V, Urso R, Cuzzi G, Barcellini L, Palmieri F, Cirillo DM, Ippolito G, Goletti D.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S25-S26. doi: 10.1016/j.ijmyco.2016.09.063. Epub 2016 Nov 11.

47.

Modulation of interferon-gamma response to QuantiFERON-TB-plus detected by enzyme-linked immunosorbent assay in patients with active and latent tuberculosis infection.

Petruccioli E, Vanini V, Chiacchio T, Cirillo DM, Palmieri F, Ippolito G, Goletti D.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S143-S144. doi: 10.1016/j.ijmyco.2016.09.029. Epub 2016 Nov 11.

48.

Modulation of CD4 and CD8 response to QuantiFERON-TB Plus in patients with active tuberculosis and latent tuberculosis infection followed over time during treatment.

Chiacchio T, Petruccioli E, Pepponi I, Vanini V, Gualano G, Cirillo D, Palmieri F, Ippolito G, Goletti D.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S141-S142. doi: 10.1016/j.ijmyco.2016.09.034. Epub 2016 Nov 11.

49.

Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.

Matucci A, Cammelli D, Cantini F, Goletti D, Marino V, Milano GM, Scarpa R, Tocci G, Maggi E, Vultaggio A.

Expert Opin Drug Saf. 2016 Dec;15(sup1):3-10. Review.

PMID:
27924646
50.

Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.

Tocci G, Goletti D, Marino V, Matucci A, Milano GM, Cantini F, Scarpa R.

Expert Opin Drug Saf. 2016 Dec;15(sup1):55-61. Review.

PMID:
27924645

Supplemental Content

Loading ...
Support Center